The present disclosure provides LNPs comprising payload molecules, e.g., mRNA therapeutics, for the treatment of diseases or disorders, which would benefit from delivery of payload molecules to airway cells.

The present disclosure provides LNPs comprising payload molecules, e.g., mRNA therapeutics, for the treatment of diseases or disorders, which would benefit from delivery of payload molecules to airway cells.

A cinnamic acid amide derivative having an excellent analgesic action is disclosed herein. The cinnamic acid amide derivative shows excellent analgesic actions to not only a nociceptive pain model animal, but also a neuropathic pain model animal, which is very useful as an agent for treating various pain diseases showing acute or chronic pains or neuropathic pains. The cinnamic acid amide derivative may be a compound represented by formula (I). ##STR00001##

The present disclosure relates to substituted hydroxystilbene compounds and derivatives, specifically 2-substituted hydroxystilbene compounds and derivatives, the synthesis of such compounds and their use in therapy.

The present disclosure relates to substituted hydroxystilbene compounds and derivatives, specifically 2-substituted hydroxystilbene compounds and derivatives, the synthesis of such compounds and their use in therapy.

The present application relates, in part, to phenyl-2-hydroxy-acetylamino-2-methylphenyl compounds, such as compounds of Formula I: ##STR00001##
or pharmaceutically acceptable salts thereof, for inhibiting PERK activity resulting in antitumor activity.